… The aim of our study was to assess the impact of rituximab on the relapse rate and … relapse
rates and disability in our retrospective study of 23 NMO patients treated with rituximab. Our …

… of rituximab 375 mg/m2 once weekly. h Clinical response rates were 46 and 48% in 2 non- …
The rate of response to rituximab appeared to be markedly higher in patients with follicular …

… The increase in T2 lesion volume was lower in the rituximab … found that rituximab reduced
the annualized relapse rate to 0.25 … , annualized relapse rates were 0.37 in the rituximab group …

… Our systematic review and meta-analysis provides evidence that rituximab therapy is
associated with reduced relapse rates and disability levels in patients with RRMS and that …

… Patients in the rituximab group, as compared with those in the placebo group, had a lower
annualized rate of relapse at 24 weeks (0.37 vs. 0.84, P=0.04) but not at 48 weeks (0.37 vs. …

… Relapse rates in DLBCL patients treated before and after the registration of rituximab and …
the use of front-line rituximab reduces the overall risk of relapse, especially late relapses. …

… (at either 57, 114, 421, or 510 days after the first rituximab dose) … relapse rates were 0.25
from baseline to week 24 and 0.18 from baseline to week 72. The mean patient relapse rate (…

… We found no differences in rate of ADAMTS13 recovery by race or treatment. We could
not evaluate the association of durability of ADAMTS13 response with RFS because of the …

… up to 3 years after rituximab infusion, with an event-free survival rate of 0.98 (95% CI 0.97–0.99)
(Figure 2A). In the same manner, the incidence rate for relapse and/or CELs remained …

… the pretreatment relapse rates were determined from disease onset rather than from a fixed
period immediately preceding rituximab therapy. Fourth, the interval between rituximab and …